Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Policy / Regulatory

China’s Health Authorities Release Third List of 41 Drugs for Recommended Generic Development

Fineline Cube Oct 31, 2023

The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...

Company Drug

CSPC Pharmaceutical Group Gains NMPA Approval for Bivalent COVID-19 mRNA Vaccine Study

Fineline Cube Oct 31, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent pharmaceutical company based in China, has announced...

Company Drug

GenFleet Therapeutics’ SLS009 Receives FDA Fast-Track Status for PTCL Treatment

Fineline Cube Oct 31, 2023

Shanghai-based biotech GenFleet Therapeutics has announced that its investigational drug SLS009 (GFH009) has received fast-track...

Company Drug

CStone Pharmaceuticals Receives NMPA Approval for Sugemalimab in R/R ENKTL

Fineline Cube Oct 31, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received a...

Company Drug

Simcere Pharmaceutical Group Secures Full Approval for Cosela in China

Fineline Cube Oct 31, 2023

Simcere Pharmaceutical Group (HKG: 2096), a leading pharmaceutical company based in China, has announced that...

Company Drug

Novartis Announces Positive Interim Results for Atrasentan in IgA Nephropathy Phase III Study

Fineline Cube Oct 31, 2023

Novartis (NYSE: NVS), a global healthcare company, has released interim results from an ongoing Phase...

Company Deals

BMS and Karyopharm Partner to Evaluate Mezigdomide and Xpovio in Relapsed/Refractory Multiple Myeloma

Fineline Cube Oct 31, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with...

Company Legal / IP

Novartis Seeks Access to Takeda’s Business Records Over Confidentiality Concerns

Fineline Cube Oct 30, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) filed a complaint with a US court last week,...

Company Drug

Roche’s Vabysmo Receives FDA Approval for Macular Edema Treatment Following RVO

Fineline Cube Oct 30, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) announced last week that it has received an indication...

Company

AbbVie’s Q3 2023 Report Shows 6.0% YOY Decline in Net Revenues

Fineline Cube Oct 30, 2023

AbbVie (NYSE: ABBV) released its Q3 2023 financial report last week, revealing a 6.0% year-on-year...

Company

Dr. Reddy’s Laboratories Reports 9% YOY Revenue Growth in Q2 2024 Fiscal Year

Fineline Cube Oct 30, 2023

India-based generics giant Dr. Reddy’s Laboratories Ltd (NYSE: RDY) has released its financial report for...

Company Medical Device

Jenscare Scientific’s Ken Valve Enters NMPA Priority Review for Aortic Valve System

Fineline Cube Oct 30, 2023

Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer based in...

Company Drug

Alphamab Oncology and 3D Medicines Gain FDA Approval for Envafolimab Phase III Trial

Fineline Cube Oct 30, 2023

Partners Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244) have announced that they have...

Company Drug

China Grand Pharma’s Lava Liquid Embolic Agent Officially Commercialized in the US

Fineline Cube Oct 30, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the official commercialization...

Company

Mindray Bio-Medical Electronics Posts Strong Q1-Q3 2023 Financial Results

Fineline Cube Oct 30, 2023

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has revealed a robust financial performance for...

Company Drug

Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs

Fineline Cube Oct 30, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval...

Company Drug

Innovent Biologics’ Mazdutide Shows Promising Weight Loss Results in Phase II Trial

Fineline Cube Oct 30, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has revealed compelling Phase II data for its weight...

Company

Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth

Fineline Cube Oct 30, 2023

French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Loqtorzi Approved by FDA for Nasopharyngeal Carcinoma

Fineline Cube Oct 30, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the US...

Company Drug

TG ImmunoPharma’s Bispecific Antibody TGI-6 Approved for Phase I Clinical Study by NMPA

Fineline Cube Oct 30, 2023

China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the National...

Posts pagination

1 … 459 460 461 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.